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Epidemiology aims to investigate both the distribution of rheumatic diseases 
and the risk factors for their development. 
Epidemiologic studies on psoriatic arthri-
tis (PsA) have long been hampered by the 
absence of widely accepted classification 
criteria. As a consequence, different stud-
ies have used different sets of criteria rang-
ing from the European Spondyloarthropa-
thy Study Group (ESSG) (1) and Wright 
& Moll (2) to ad hoc criteria, all of which 
are prone to some degree to misclassifying 
patients. In particular, the ESSG criteria 
have a relatively low sensitivity and speci-
ficity (1), while the Moll and Wright crite-
ria tend to be overinclusive (2). The recent 
development of the CASPAR (ClASsifica-
tion criteria for Psoriatic ARthritis) crite-
ria has provided a more robust framework 
for conducting epidemiological studies in 
PsA given the high sensitivity (0.91) and 
specificity (0.99) of these criteria (3). In 
addition, the CASPAR criteria have been 
validated quite extensively and have been 
shown to perform well, at least in estab-
lished PsA (3, 4). However, only a small 
minority of epidemiological studies in PsA 
have used the CASPAR criteria. 
Other discrepancies between published 
studies include different study settings, de-
signs, and ascertainment methods. These 
differences render difficult to compare the 
results from different studies, which have 
found widely varying estimates of inci-
dence (from 3,02 to 23,1 cases per 100,000 
people) and prevalence (from 49,1 to 420 
cases per 100,000 people) (5-30). On the 
other hand, some differences may be genu-
ine and reflect genetic or environmental 
factors. For instance, the frequency of PsA 
has consistently been reported to be quite 
low (up to 1/100,000) in Japan (7). 
Most incidence studies available are retro-
spective in design and have used either med-
ical records or else diagnostic or insurance 
codes to determine the incidence of PsA 
in general or Hospital populations (5-15) 
(Table I). Prospective studies have usually 
yielded higher incidence rates than retro-
spective studies. Data from a population-
based incidence cohort suggests a rise of the 
incidence of PsA over the last three decades 
(12). However, it is debatable whether this 
rising incidence is genuine or simply re-
flects a greater awareness of physicians. 
As for prevalence studies, the majority 
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SUMMARY
Epidemiological studies on psoriatic arthritis have long been hampered by the absence of widely accepted 
classification criteria. The development of the CASPAR (ClASsification criteria for Psoriatic ARthritis) criteria 
has recently provided the framework for conducting epidemiological studies in psoriatic arthritis using uniform 
recruitment criteria. However, so far, only a minority of studies have adopted such criteria. In addition to the 
lack of shared classification criteria, differences in study settings, designs, and ascertainment methods have 
contributed to yield substantial disparities in the estimates of the incidence (from 3,02 to 23,1 cases per 100,000 
people) and prevalence (from 49,1 to 420 cases per 100,000 people) of psoriatic arthritis around the globe. 
Overall, the available data suggests that the prevalence of psoriasis in the general population is approximately 
2-3%, with about a third of patients with psoriasis having arthritis. Therefore, psoriatic arthritis may affect 0,3-
1,0% of the population, a frequency not dissimilar from that of rheumatoid arthritis. Future epidemiological 
studies should be carried out in larger numbers of patients diagnosed using consistent criteria. 
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is cross-sectional and population-based, 
while a minority is retrospective and based 
on medical records. A few studies have ex-
amined the prevalence of PsA in the pop-
ulation of people with psoriasis. Recent 
cross-sectional surveys tend to yield higher 
prevalence estimates than retrospective 
prevalence studies. (5-30) (Table II). 
Many studies have reported that the onset 
of psoriasis typically precedes the devel-
opment of arthritis. Approximately 85% 
of patients develop psoriasis prior to ar-
thritis, while in 5-10% of patients both 
conditions develop simultaneously, and in 
5-10% arthritis precedes psoriasis. There 
is some evidence suggesting that the se-
verity of psoriasis is associated with an in-
creased risk, although not greater severity 
of arthritis (31).
The prevalence of psoriasis in the general 
population is circa 2-3%, with about a third 
of patients with psoriasis having arthritis. 
Table I - incidence studies of PsA.
Incidence of PsA in Population
Country Type of study Method Criteria Annual Incidence 
Cases/105 (95%CI)
Ref.


























Greece (2003) retrospective Hospital system
records
eSSG 3.02 (1.55–4.49) 9
Finland (2003) Prospective
popul.-based




















CASPAr 7.2 (6.0 - 8.4) 12
















CASPAr 6.26 (4.2 - 8.3) 15
Incidence of PsA in Psoriasis
Country Type of study Method Criteria Incidence estimate 
% (95%CI)
Ref.
USA (2009) Popul.based 
retrospective
diagnostic codes + 
medical records
CASPAr 2,7% (2,1-3,5%)
3.1% after 10 years
5.1% after 20 years
16
UK, italy, France, 
Spain and Germany
(2010)
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Therefore, PsA may occur in 0.3-1.0% of 
the population, a frequency similar to that 
of rheumatoid arthritis. (see Table 1-2).
Genetic factors have been linked to both 
psoriasis and PsA. In particular, HLA-B13, 
B16 and its splits HLA-B38 and HLA-
Table II - Prevalence studies of PsA.
Prevalence of PsA in Population





Medical system records Arthritis + psoriasis 101 (81-121) 6
Japan (2001) retrospective Nationwide questionnaire Amor and eSSG ~1,0 7
Northwest
Greece (2003)
retrospective Medical system records eSSG 56.6 (49.9-63.2) 9
Australia (2004) retrospective
Popul.-based
Questionnaire Psoriasis + arth/tenos/back 
pain/dact/enth





eSSG 170 (100-240) 20
France (2005) Cross-sectional
Popul.-based
Telephone questionnaire + 
physical exam





Arthrhitis/spinal inv + Psoriasis 420 (310-610) 22
USA (2005) Cross-sectional Questionnaire Patient’s
Self-report
250 (180-310) 23
iCeLAND (2007) Cross-sectional interview +
clin. exam. +
medical records
Psoriasis + Arthrhitis 139 (112–169) 24
CHiNA (2008) retrospective
Popul.-based
Medical system records eSSG - Amor ~ from 10 to 100 25










Medical records (r.e.P.) CASPAr 158 (132-185) 12
Norway (2009) retrospective Diagnostic
iCD-codes
Psoriasis + Arthrhitis 127 (106–154) 13
Czech republiic (2010) Popul.-based
Prospective





CASPAr 74 (57-94) 15
Prevalence of PsA in Psoriasis
Country Type of study Method Criteria Prevalence estimate % 
(95%CI)
Ref.
iTALY (1984) Cross-sectional Dermatologic clinic Moll & wright’s 34% 26






iTALY (2005) Cross-sectional Hospitalized patients eSSG 7.7% (6.0-9.5%) 28
USA (2005) Cross-sectional Questionnaire Patient’s
Self-report
11% (9-14%) 23
Germany (2009) Prospective cross-
sectional
dermatol. centres Moll & wright 20.6%(18.6-22.7%) 29
UK (2009) Prospective cross-
sectional
Questionnaire+ clin. exam. CASPAr 13.8% (7,1-24.1%) 30
UK - italy, France, Spain 
and Germany (2010)
Cross-sectional Adelphy Psoriasis Program
Questionnaire
Psoriasis + Arthrhitis 8.1% 17
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B39, B17, and Cw6 have been associated 
with psoriasis, while HLA-B7 and B27 
have been associated with PsA (32). 
Some environmental factors, including 
HIV infection, trauma, and psychological 
stress appear to increase susceptibility to 
developing PsA. In addition, a number of 
clinical features including nail dystrophy, 
scalp lesions, and intergluteal/perianal pso-
riasis have been mapped to a higher likeli-
hood of PsA (16). 
Patients with PsA have been found to have 
increased risk factors for cardiovascular 
disease including hypertension, dyslip-
idemia and insulin resistance (33). Other 
studies have shown subclinical atheroscle-
rosis and an atherogenic lipid profile (34-
36). There is an increased prevalence of the 
metabolic syndrome in patients with pso-
riasis, particularly in those with moderate 
to severe skin disease (37).
Studies that have investigated mortality in 
PsA have thus far produced conflicting re-
sults, with a community-based study show-
ing no increase in mortality (6, 12) while 
the analysis of a hospital-based cohort es-
timated a combined Standardized Mortality 
Ratio (SMR) for both men and women to 
be 1.62 (38). Recently, a single-center study 
suggested that mortality rates in the PsA 
cohort were not significantly different from 
those of the UK general population (39).
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